Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?

Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg; Russel J. Reiter

doi:10.1007/s40262-016-0386-3

Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?

Lars Peter Holst Andersen, Ismail Gögenur, Jacob Rosenberg, Russel J. Reiter

Institut for Klinisk Medicin

12 Citationer (Scopus)

Abstract

Despite widespread clinical application of melatonin, several unanswered questions remain regarding the pharmacokinetics of this drug. This lack of knowledge may contribute to the inconsistency of results in previous clinical studies. Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established. Several questions relate to what constitutes a clinically effective plasma concentration, the choice of ideal administration route, and the optimal method of analysis. Furthermore, investigations of melatonin metabolites in humans are urgently needed in order to characterize their biological functions and the metabolic fates of these derivatives. Finally, pharmacokinetics in patients should be investigated further in order to reduce the risk of potential adverse effects, such as daytime sleepiness or unintended sedation.

Originalsprog	Engelsk
Tidsskrift	Clinical Pharmacokinetics
Vol/bind	55
Udgave nummer	9
Sider (fra-til)	1027-30
Antal sider	4
ISSN	0312-5963
DOI	https://doi.org/10.1007/s40262-016-0386-3
Status	Udgivet - 1 sep. 2016

Adgang til dokumentet

10.1007/s40262-016-0386-3

Citationsformater

@article{d69d23a9d3a2445180704c378d229de9,

title = "Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?",

abstract = "Despite widespread clinical application of melatonin, several unanswered questions remain regarding the pharmacokinetics of this drug. This lack of knowledge may contribute to the inconsistency of results in previous clinical studies. Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established. Several questions relate to what constitutes a clinically effective plasma concentration, the choice of ideal administration route, and the optimal method of analysis. Furthermore, investigations of melatonin metabolites in humans are urgently needed in order to characterize their biological functions and the metabolic fates of these derivatives. Finally, pharmacokinetics in patients should be investigated further in order to reduce the risk of potential adverse effects, such as daytime sleepiness or unintended sedation.",

keywords = "Journal Article",

author = "Andersen, {Lars Peter Holst} and Ismail G{\"o}genur and Jacob Rosenberg and Reiter, {Russel J.}",

year = "2016",

month = sep,

day = "1",

doi = "10.1007/s40262-016-0386-3",

language = "English",

volume = "55",

pages = "1027--30",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Adis International Ltd",

number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of Melatonin

T2 - The Missing Link in Clinical Efficacy?

AU - Andersen, Lars Peter Holst

AU - Gögenur, Ismail

AU - Rosenberg, Jacob

AU - Reiter, Russel J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Despite widespread clinical application of melatonin, several unanswered questions remain regarding the pharmacokinetics of this drug. This lack of knowledge may contribute to the inconsistency of results in previous clinical studies. Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established. Several questions relate to what constitutes a clinically effective plasma concentration, the choice of ideal administration route, and the optimal method of analysis. Furthermore, investigations of melatonin metabolites in humans are urgently needed in order to characterize their biological functions and the metabolic fates of these derivatives. Finally, pharmacokinetics in patients should be investigated further in order to reduce the risk of potential adverse effects, such as daytime sleepiness or unintended sedation.

AB - Despite widespread clinical application of melatonin, several unanswered questions remain regarding the pharmacokinetics of this drug. This lack of knowledge may contribute to the inconsistency of results in previous clinical studies. Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established. Several questions relate to what constitutes a clinically effective plasma concentration, the choice of ideal administration route, and the optimal method of analysis. Furthermore, investigations of melatonin metabolites in humans are urgently needed in order to characterize their biological functions and the metabolic fates of these derivatives. Finally, pharmacokinetics in patients should be investigated further in order to reduce the risk of potential adverse effects, such as daytime sleepiness or unintended sedation.

KW - Journal Article

U2 - 10.1007/s40262-016-0386-3

DO - 10.1007/s40262-016-0386-3

M3 - Comment/debate

C2 - 27000757

SN - 0312-5963

VL - 55

SP - 1027

EP - 1030

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

IS - 9

ER -

Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater